13th Annual Industry Audit
Pharm Exec ranks the top 25 pharma companies based on more than a dozen key metrics to uncover the industry’s top performer in delivering shareholder value. A hint: it’s the smaller, more focused players that stand out—we call it the “stealth effect."

Ireland Roundtable
A panel of leading local thought leaders from industry, government, the CRO community, and academia review the country's future as a magnet for life science investments. Will Ireland remain the world’s leading exporter of finished pharmaceutical products? Will the government be able to retain its heralded tax and investment incentives as the European Union moves to crack down on member state subsidies? What is being done to keep Ireland’s high labor costs under control while maintaining a productive, highly skilled workforce? The bottom line: as a small country that in pharma punches way above its weight globally, the stakes for big pharma in the outcome of Irish industrial policy are, yes, big.

“C-suite” Coaching
Experts in the field of executive coaching offer tips in helping hard-pressed members of the “C-suite” realize their potential in an industry undergoing significant restructuring of both human and financial capital.

Med Affairs a Value Driver
Many drugmakers still think the goal of Medical Affairs Departments should be to limit and control the content granted to external stakeholders. However, as these relationships become more complicated, the role of Medical Affairs is taking on greater importance in the value chain. Column highlights this evolution.

Washington Report
Pharm Exec examines the latest developments surrounding the controversial federal 340B drug discount program. Pharma companies are pushing back against expansion of 340B for hospitals and health clinics, as the program has grown in recent years to cover more providers, including many large cancer centers. A legal battle has erupted over whether the program applies to orphan drugs, and whether Congress intended for the program to shift funds from rich drug companies to organizations providing healthcare for the poor.